Increased risk of chemotherapy-associated venous thromboembolism in elderly patients with cancer

Matteo Vergati, David Della-Morte, Patrizia Ferroni, Vittore Cereda, Livia Tosetto, Francesca La Farina, Fiorella Guadagni, Mario Roselli

Research output: Contribution to journalArticlepeer-review


Data on the relationship between aging, chemotherapy, and risk for venous thromboembolism (VTE) are controversial. We sought to evaluate the risk of chemotherapy-associated VTE in young to middle-aged (YMA) and elderly cancer patients and to analyze the VTE-free survival time in both groups. Patients with histologically confirmed diagnosis of solid malignancy receiving any type of systemic chemotherapy, no clinical diagnosis of VTE before chemotherapy initiation, and Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2 were enrolled in this study. Of the 486 consecutive patients included in the study, 380 (78%) were classified as YMA (≤70 years of age) and 106 (22%) as elderly (>70 years of age). At a median follow-up of 1 year, the incidence of VTE events was almost two-fold greater in elderly than in YMA (11% vs. 6%). Age (≤70 years vs. >70 years (hazard ratio [HR], 2.42; 95% confidence interval [CI] 1.15-5.06; p=0.020), ECOG-PS (HR, 6.54; 95% CI 3.10-13.8; p

Original languageEnglish
Pages (from-to)224-231
Number of pages8
JournalRejuvenation Research
Issue number3
Publication statusPublished - Jun 1 2013

ASJC Scopus subject areas

  • Ageing
  • Geriatrics and Gerontology


Dive into the research topics of 'Increased risk of chemotherapy-associated venous thromboembolism in elderly patients with cancer'. Together they form a unique fingerprint.

Cite this